Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Glenn Belkin

Developmental - Behavioral Pediatrics Valhalla, NY Doctor of Osteopathy

NPI 1114914611 CMS profile 50561

503 Grasslands Rd, Ste 200, Valhalla, NY 10595

Open in the dashboard

General payments

$2,127

93 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Glenn Belkin of Valhalla, NY is reported in the CMS Open Payments database as having received $2,127 across 93 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Developmental - Behavioral Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $94 5
2024 General $113 6
2023 General $175 10
2022 General $159 8
2021 General $780 17
2020 General $267 17
2019 General $539 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Glenn Belkin
  • Developmental - Behavioral Pediatrics median
  • Middle half of Developmental - Behavioral Pediatrics
  • National median

In program year 2025, general payments to Glenn Belkin were reported at $94. Among 160 Developmental - Behavioral Pediatrics profiles paid that year, the median was $77 and the middle half received between $27 and $211.

Show as a table
Year Glenn Belkin Developmental - Behavioral Pediatrics median Middle half National median
2019 $539 $106 $28–$315 $163
2020 $267 $55 $19–$181 $114
2021 $780 $96 $25–$343 $132
2022 $159 $86 $23–$235 $149
2023 $175 $71 $25–$348 $160
2024 $113 $74 $25–$237 $164
2025 $94 $77 $27–$211 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Tris Pharma Inc $699 42 payments
  2. Supernus Pharmaceuticals, Inc. $653 7 payments
  3. Ironshore Pharmaceuticals Inc. $528 28 payments
  4. Corium, Inc. $79 6 payments
  5. Vertical Pharmaceuticals, LLC $56 3 payments
  6. Adlon Therapeutics L.P. $33 2 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $32 2 payments
  8. Shire North American Group Inc $16 1 payment
  9. Collegium Pharmaceutical, Inc. $16 1 payment
  10. ACADIA Pharmaceuticals Inc $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,627 92 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $500 1 payment
Products named General payments · program years 2019–2025
  1. Quillivant XR $351 22 payments
  2. JORNAY PM Central Nervous Stimulant ADHD $250 15 payments
  3. Jornay PM 20mg capsules (Bottle of 100) $213 10 payments
  4. Quillivant $162 10 payments
  5. QELBREE $106 5 payments
  6. Dyanavel XR Adhd $81 5 payments
  7. Azstarys $79 6 payments
  8. JORNAY PM Central Nervous System Stimulant $65 3 payments
  9. Dyanavel XR Adhd $65 3 payments
  10. Relexxii $36 2 payments
  11. Other $191 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

11

Median for Pediatric Medicine: 38

Drug cost

$1,179

Median for Pediatric Medicine: $2,769

Branded share of claims

0%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sertraline Hcl Generic 11 $1,179

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $39
$39 — —
Dyanavel XR
  • Tris Pharma Inc $22
$22 — —
Quillichew ER
  • Tris Pharma Inc $19
$19 — —
Relexxii
  • Vertical Pharmaceuticals, LLC $17
$17 — —
Azstarys
  • Corium, Inc. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

93 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Developmental - Behavioral Pediatrics in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record